BR112015027373A2 - Processo de expressão - Google Patents

Processo de expressão

Info

Publication number
BR112015027373A2
BR112015027373A2 BR112015027373A BR112015027373A BR112015027373A2 BR 112015027373 A2 BR112015027373 A2 BR 112015027373A2 BR 112015027373 A BR112015027373 A BR 112015027373A BR 112015027373 A BR112015027373 A BR 112015027373A BR 112015027373 A2 BR112015027373 A2 BR 112015027373A2
Authority
BR
Brazil
Prior art keywords
target polypeptide
expression
expression vector
expressing
expression process
Prior art date
Application number
BR112015027373A
Other languages
English (en)
Portuguese (pt)
Inventor
Louise Dodds Anna
Vallabh Kara Bhupendra
Louise Saunders Fay
Marie Geraldine Bayard Adeline
Original Assignee
Fujifilm Diosynth Biotechnologies Uk Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB201308017A external-priority patent/GB201308017D0/en
Priority claimed from GB201320339A external-priority patent/GB201320339D0/en
Application filed by Fujifilm Diosynth Biotechnologies Uk Ltd filed Critical Fujifilm Diosynth Biotechnologies Uk Ltd
Publication of BR112015027373A2 publication Critical patent/BR112015027373A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • C07K16/065Purification, fragmentation
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3076Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
    • C07K16/3092Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/10Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14Specific host cells or culture conditions, e.g. components, pH or temperature
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/01Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02Fusion polypeptide containing a localisation/targetting motif containing a signal sequence

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
BR112015027373A 2013-05-03 2014-04-29 Processo de expressão BR112015027373A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB201308017A GB201308017D0 (en) 2013-05-03 2013-05-03 Expression process
GB201320339A GB201320339D0 (en) 2013-11-18 2013-11-18 Expression Process
PCT/GB2014/000165 WO2014177826A1 (en) 2013-05-03 2014-04-29 Expression process

Publications (1)

Publication Number Publication Date
BR112015027373A2 true BR112015027373A2 (pt) 2017-08-29

Family

ID=50639794

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015027373A BR112015027373A2 (pt) 2013-05-03 2014-04-29 Processo de expressão

Country Status (12)

Country Link
US (3) US9873891B2 (enExample)
EP (1) EP2992104B1 (enExample)
JP (1) JP6545153B2 (enExample)
KR (1) KR102180660B1 (enExample)
CN (2) CN105392889A (enExample)
BR (1) BR112015027373A2 (enExample)
CA (1) CA2910877C (enExample)
DK (1) DK2992104T3 (enExample)
ES (1) ES2732907T3 (enExample)
RU (1) RU2731717C2 (enExample)
SG (1) SG11201508447TA (enExample)
WO (1) WO2014177826A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3323826A1 (en) * 2016-11-21 2018-05-23 Danmarks Tekniske Universitet Native chinese hamster ovary cell secretion signal peptides for production of recombinant polypeptides
EP3725877A4 (en) 2017-12-11 2021-02-17 FUJIFILM Corporation ANIMAL CELLS AS WELL AS A METHOD FOR MANUFACTURING THE SAME, AND A METHOD FOR MANUFACTURING TARGET PROTEIN
JP7123168B2 (ja) 2018-12-11 2022-08-22 富士フイルム株式会社 動物細胞、動物細胞の製造方法および目的タンパク質の製造方法
CN109837277A (zh) * 2019-03-01 2019-06-04 深圳生生凡非基因技术有限公司 一种cpgk嵌合型启动子、腺相关病毒载体及其应用
EP4067474A4 (en) 2019-11-29 2023-01-18 FUJIFILM Corporation CELL CULTURE METHOD, ANTIBODY PRODUCTION METHOD, ORGANIC ACID AND ANTIBODY REMOVAL METHOD
WO2022149607A1 (ja) 2021-01-07 2022-07-14 富士フイルム株式会社 細胞の選択方法、装置、及び装置システム
JPWO2022196710A1 (enExample) 2021-03-17 2022-09-22
CN112980852B (zh) * 2021-05-18 2021-08-13 北京华芢生物技术有限公司 新型冠状病毒b.1.351南非突变株rbd的基因及其应用
WO2022249089A1 (en) 2021-05-27 2022-12-01 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
WO2023054556A1 (ja) 2021-09-30 2023-04-06 富士フイルム株式会社 細胞培養方法、及び有用物質の製造方法
EP4450609A1 (en) 2021-12-15 2024-10-23 FUJIFILM Corporation Method for producing product, and cell culture apparatus
JPWO2023190300A1 (enExample) 2022-03-28 2023-10-05
WO2023190829A1 (ja) 2022-03-31 2023-10-05 富士フイルム株式会社 生産物の製造方法、及び生産物
JPWO2023238949A1 (enExample) 2022-06-10 2023-12-14
EP4596704A1 (en) 2022-09-29 2025-08-06 FUJIFILM Corporation Method for producing product
WO2024248120A1 (ja) 2023-05-31 2024-12-05 富士フイルム株式会社 生産物の生産方法
WO2024248118A1 (ja) 2023-05-31 2024-12-05 富士フイルム株式会社 細胞培養方法および生産物の製造方法
CN121175432A (zh) 2023-05-31 2025-12-19 富士胶片株式会社 生产物的生产方法
WO2025244971A1 (en) 2024-05-20 2025-11-27 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003093295A2 (en) * 2002-04-30 2003-11-13 University Of North Carolina At Chapel Hill Secretion signal vectors
US7186699B2 (en) * 2003-06-03 2007-03-06 Cell Genesys, Inc. Method for treating cancer by vector-mediated delivery of one or more anti-angiogenic or pro-apoptotic genes
US8029783B2 (en) * 2005-02-02 2011-10-04 Genentech, Inc. DR5 antibodies and articles of manufacture containing same
EP1739179A1 (en) * 2005-06-30 2007-01-03 Octapharma AG Serum-free stable transfection and production of recombinant human proteins in human cell lines
GB0602173D0 (en) * 2006-02-03 2006-03-15 Avecia Ltd Expression system
MX2009007139A (es) * 2006-12-28 2009-10-08 Centocor Ortho Biotech Inc Metodos y vectores para generar inmunoglobulinas no sialiladas.
KR101618767B1 (ko) * 2008-09-02 2016-05-09 한국생명공학연구원 외래단백질을 고효율로 생산하는 리더서열
CN102272160A (zh) * 2008-12-31 2011-12-07 印度血清及疫苗有限公司 抗rhd单克隆抗体
TW201613969A (en) 2009-03-05 2016-04-16 Abbvie Inc IL-17 binding proteins
GB0905331D0 (en) * 2009-03-27 2009-05-13 Avecia Biolog Ltd Expression process
KR101420274B1 (ko) * 2011-06-13 2014-07-21 주식회사 종근당 Csp-b 5'sar 인자를 포함하는 동물세포 발현 벡터 및 이를 이용한 재조합 단백질의 제조방법

Also Published As

Publication number Publication date
WO2014177826A1 (en) 2014-11-06
CA2910877C (en) 2021-08-03
US11306323B2 (en) 2022-04-19
RU2015151626A (ru) 2017-06-08
CA2910877A1 (en) 2014-11-06
CN114395584B (zh) 2025-01-28
JP6545153B2 (ja) 2019-07-17
EP2992104A1 (en) 2016-03-09
JP2016517691A (ja) 2016-06-20
EP2992104B1 (en) 2019-04-17
SG11201508447TA (en) 2015-11-27
US9873891B2 (en) 2018-01-23
KR102180660B1 (ko) 2020-11-19
US20180127777A1 (en) 2018-05-10
US20220213500A1 (en) 2022-07-07
US20160076051A1 (en) 2016-03-17
RU2015151626A3 (enExample) 2018-03-20
RU2731717C2 (ru) 2020-09-08
CN105392889A (zh) 2016-03-09
KR20160003705A (ko) 2016-01-11
DK2992104T3 (da) 2019-07-15
CN114395584A (zh) 2022-04-26
ES2732907T3 (es) 2019-11-26

Similar Documents

Publication Publication Date Title
BR112015027373A2 (pt) Processo de expressão
PE20171142A1 (es) Vectores para expresion de antigenos asociados a prostata
MX371025B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
GB2502937A (en) Running a plurality of instances of an application
IN2015DN02771A (enExample)
CL2012003014A1 (es) Acido nucleico aislado que codifica un receptor pyr/pyl mutado; polipeptido codificado por dicho acido nucleico; casette y vector de expresión que comprenden el polinucleotido descrito anteriormente y metodo para aumentar la tolerancia al estrés en una planta.
NZ717647A (en) Structure based predictive modeling
CL2016000232A1 (es) Estabilización de polipéptidos que contienen fragmentos cristalizables
BR112019008484A2 (pt) circuito, estação base, método realizado por um processador, e, mídia de gravação.
AR089571A1 (es) Metodos y aparatos de codificacion de datos de video
MX2015012875A (es) Composiciones de cultivo celular con antioxidantes y metodos para la produccion de polipeptidos.
BR112016008830A2 (pt) Método para produzir uma substância alvo
BR112013032037A2 (pt) método para processar uma solicitação de pesquisa, meio legível por computador, programa legível por computador e sistema para processar uma solicitação de pesquisa
BR112015030435A8 (pt) computador, artigo de fabricação e processo para proporcionar temporizadores por processador virtuais para sistemas de processador múltiplo
BR112016024895A2 (pt) fator secretório de proteína com alta eficácia secretória e um vetor de expressão compreendendo o mesmo
AR087103A1 (es) Tecnologia de simulacion integrada
MX2016006816A (es) Promotores sinteticos para celulas de ovario de hamster chino (cho), metodos de produccion de promotores sinteticos usando modulos de sitio de union del factor de transcripcion.
GB201305554D0 (en) Implementing remapping command with indirection update for indirected storage
BR112016012229A2 (pt) métodos de produção de polipeptídeos
MX373329B (es) Células eucariotas novedosas y métodos para la expresión recombinante de un producto de interés.
BR112018009732A8 (pt) ?polinucleotídeo, vetor de vírus adeno-associado, partícula de vírus adeno-associado, célula hospedeira, métodos para produzir uma partícula de vírus adeno-associado, para tratar hemofilia a, para transduzir uma célula hospedeira, e, uso de uma partícula de vírus adeno-associado?
EA202190244A3 (ru) Сверхэкспрессия регуляторов пути n-гликозилирования для модуляции гликозилирования рекомбинантных белков
AR097805A1 (es) Células de cambio de temperatura para la expresión de alto rendimiento de polipéptidos en levadura y otros transformados
BR112018005464A2 (pt) expressão de proteínas contendo fc
MX2016016565A (es) Polipeptidos de fusion relacionados con omega-hidroxilasa con propiedades mejoradas.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]

Free format text: MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.MANTIDO O INDEFERIMENTO UMA VEZ QUE NAO FOI APRESENTADO RECURSO DENTRO DO PRAZO LEGAL.